Go Pro
NASDAQ:CDIO

Cardio Diagnostics Q2 2026 Earnings Report

Cardio Diagnostics logo
$1.88 -0.06 (-2.85%)
As of 10:27 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Cardio Diagnostics EPS Results

Actual EPS
-$0.51
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cardio Diagnostics Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cardio Diagnostics Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Cardio Diagnostics' next earnings date is estimated for Friday, November 6, 2026, based on past reporting schedules.

Conference Call Resources

Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardio Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardio Diagnostics and other key companies, straight to your email.

About Cardio Diagnostics

Cardio Diagnostics (NASDAQ:CDIO) develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

View Cardio Diagnostics Profile